What changed
$QGEN — ADD 📊
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
🎯 Q1 FY26 | EPS $0.54 vs $0.54 ➖
💡 Consensus expects low-single-digit revenue growth and flattish EPS for 2026 (P/E 17x), but we see 5–7% organic growth stabilizing with biopharma demand recovery and cost measures adding $0.10–0.15 to annual EPS, justifying a P/E of 19–21x, in line with the reference class of recovering tools companies.
📉 Reward/Risk: 2.3:1
🏢 Business Quality: 7/10 - Installed base and switching costs support defensive 65%+ recurring revenue, but growth is mature and competitive intensity in NGS/precision medicine caps upside.
📊 Valuation: cheap — P/E 17x vs. peers 20–25x, EV/EBITDA 12x vs.
📊 Our read: ADD. Full analysis →
https://stockduty.xyz/s/QGEN0619